IL-10 from Tumoral B Cells Modulates the Diffuse Large B-Cell Lymphoma Microenvironment and Response to Immunotherapy.

Researchers showed that IL-10–deficient lymphomas acquire a highly immunosuppressed and T-cell–exhausted microenvironment with increased angiogenesis that results in a more aggressive phenotype, which is refractory to PD-1 immune checkpoint blockade.